Open Access<p>Wogonoside Attenuates Cutaneous Squamous Cell Carcinoma by Reducing Epithelial–Mesenchymal Transition/Invasion and Cancer Stem-Like Cell Property</p>
Author(s) -
Xiuyong Wang,
Yuan Chang,
Ming Gao,
Fan Zhang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s251806
Subject(s) - epithelial–mesenchymal transition , cd44 , in vivo , wnt signaling pathway , cancer research , angiogenesis , pi3k/akt/mtor pathway , chemistry , protein kinase b , mesenchymal stem cell , cancer stem cell , cell , apoptosis , cancer , pathology , medicine , biology , signal transduction , biochemistry , metastasis , microbiology and biotechnology
Cutaneous squamous cell carcinoma (cSCC) is the most common second basal cell carcinoma in our population. Wogonoside, the main in vivo metabolite of wogonin, possesses anti-inflammatory, anti-angiogenesis and anti-cancer activities. Nevertheless, the effectiveness of wogonoside therapy on cSCC has not been clarified.